Linking these metabolic events to therapeutic response in patients, PGC1α expression is induced in BRAFV600 melanoma patients treated with BRAF inhibitors, either alone [14] or in combination with MEK inhibitors [15], whilst an elevated mitochondrial biogenesis signature is observed in tumours that relapse following MAPK inhibitor treatment [16]. Here, MAP2K7 is linked to melanoma.